Welcome to our dedicated page for Elutia news (Ticker: ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. (Nasdaq: ELUT) is a regenerative medicine company that develops drug-eluting biomatrix products to improve compatibility between implantable medical devices and patients. The ELUT news feed on Stock Titan aggregates company-issued updates, regulatory disclosures and other coverage so readers can follow how Elutia’s biomatrix platform and business strategy are evolving over time.
Recent Elutia news has focused on its NXT-41 and NXT-41x biomatrix programs in plastic and reconstructive surgery, particularly breast reconstruction. Press releases describe NXT-41 as a novel base matrix and NXT-41x as an antibiotic-eluting version built on a platform that was clinically and commercially validated with EluPro, which the company sold to Boston Scientific as part of its BioEnvelope business divestiture. News items also discuss expected regulatory milestones for these products and the company’s intention to use proceeds from asset sales to fund development and commercialization.
Investors and observers can also find coverage of financial results and capital structure changes, including quarterly earnings press releases, the impact of the $88 million BioEnvelope sale, repayment of secured debt, and updates on cash balances described in preliminary financial announcements. Additional news includes information on board changes, conference presentations, and published clinical data on biologic envelopes used with cardiac implantable electronic devices, which illustrate how Elutia’s biomatrix technology has performed in prior applications.
Because Elutia operates in a regulated medical and biotech environment, its news often touches on clinical evidence, FDA-related expectations, litigation updates and Nasdaq listing matters, such as the November 2025 notice regarding minimum bid price compliance. Bookmarking this ELUT news page provides a single location to review Elutia’s ongoing disclosures about its drug-eluting biomatrix platform, strategic transactions and progress in targeted surgical markets.
Elutia (Nasdaq: ELUT) announced inducement equity awards granted March 10, 2026 to three new employees under its 2026 Inducement Award Plan.
An aggregate of 460,000 non-qualified stock options were granted with a $1.09 exercise price (closing price on March 10, 2026). Options vest 25% after one year, then monthly over three years, subject to continued employment and plan terms.
Elutia (Nasdaq: ELUT) reported fourth-quarter and full-year 2025 results and initiated the regulatory process for its NXT-41 base biologic. The company submitted a 510(k) for NXT-41 and expects FDA clearance in H2 2026, with full NXT-41x drug-eluting clearance anticipated in 1H 2027.
Key financials: $88.0 million BioEnvelope sale closed, transformed balance sheet with $36.4 million cash plus $8.0 million escrowed proceeds, and full repayment of a $26.9 million loan facility.
Elutia (Nasdaq: ELUT) announced on March 4, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price) and Rule 5550(b)(2) (minimum market value of listed securities).
Nasdaq advised the company is now in full compliance with continued listing requirements and that these matters are closed, and Elutia’s Class A common stock will remain listed and traded on the Nasdaq Capital Market under the symbol ELUT.
Elutia (Nasdaq: ELUT) named Pete Ligotti Chief Commercial Officer to lead commercialization of NXT-41x, a next-generation antibiotic-eluting biomatrix targeting post-mastectomy reconstruction. The company cites a ~$1.5B U.S. breast reconstruction market, ~162,000 annual procedures, >80% biologic mesh usage, and persistent infection rates of 15–20%. Elutia is preparing for anticipated FDA clearance in 2027 and will focus on market penetration and reimbursement strategy ahead of launch.
Elutia (NASDAQ: ELUT) will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Management will host a conference call and webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT.
A live and archived webcast will be available in the Investors section at http://investors.elutia.com/. Registered participants receive dial-in details and a PIN, and the system can dial out when the call begins.
Elutia (Nasdaq: ELUT) earned 2026 Great Place to Work Certification, recognizing high-trust culture, sustained engagement, and retention in a regulated, innovation-driven company.
Workforce highlights: women 54% of employees and 62% of leaders, median tenure 6.3 years, half hold advanced degrees, one-third hold doctorates. The release cites prior leadership commercial successes, including an $88 million asset sale and $1.5 billion in products brought to market.
Elutia (Nasdaq: ELUT) reported preliminary Q4 2025 results and corporate updates on its NXT-41x program.
Key items: Q4 net sales ~$3.3M (+16% YoY); sale of BioEnvelope to Boston Scientific for $88M completed October 2025; $26.9M of secured debt repaid in Q4; cash and escrowed proceeds totaled $44.3M at 12/31/2025 (cash on hand ~$36.3M plus $8.0M escrow). Elutia plans an FDA filing for NXT-41 in H1 2026 with potential clearance H2 2026 and anticipates FDA clearance of antibiotic-eluting NXT-41x in H1 2027.
Elutia (Nasdaq: ELUT) will present at the Virtual Global BioInnovation Forum during the JP Morgan Healthcare Conference on Jan 13, 2026 at 10:00 a.m. PT / 1:00 p.m. ET. The company will highlight progress on NXT-41x, a next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgery that builds on Elutia's validated biomatrix platform.
Presentation speakers are Randy Mills, PhD, CEO of Elutia, and Christopher Reid, MD, a plastic surgeon and researcher from UC San Diego Health, who will discuss unmet needs in breast reconstruction, including postoperative infection rates up to 25% and serious complication rates affecting one in three patients. A live and archived webcast will be available in the Investors section at investors.elutia.com.
Elutia (Nasdaq: ELUT) reported Q3 2025 results and closed the sale of its BioEnvelope business to Boston Scientific for $88 million (received $80.3 million at closing on Oct 1, 2025). Proceeds were used to pay off a loan ($27.8M) and fund development of NXT-41x, an antibiotic-eluting biomatrix targeting a ~$1.5B U.S. plastic/reconstructive surgery market. Financials: Q3 net sales were $3.3M (Q3 2024: $3.7M); GAAP gross margin improved to 55.8% (Q3 2024: 48.9%). Cash was $4.7M at Sept 30, 2025, with an additional $8M held in escrow.
Elutia (Nasdaq: ELUT) announced it will release third quarter 2025 financial results after market close on Thursday, November 6, 2025. The company said management will host a conference call and webcast the same day starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. Participants must register to receive a dial-in number and personalized PIN; registrants can also opt for a dial-out when the call begins.
A live and archived webcast will be available in the company’s Investors section at http://investors.elutia.com/. Attendees are asked to log in about 10 minutes before the scheduled start time.